NASDAQ:OKUR OnKure Therapeutics Q4 2024 Earnings Results & Report $2.34 -0.02 (-0.64%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more. OnKure Therapeutics missed analyst earnings expectations in its Q4 2024 results, released March 10, 2025. The company reported EPS of -$1.37 versus the -$0.86 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 10, 2025TimeAfter Market Closes OnKure Therapeutics EPS ResultsActual EPS-$1.37Consensus EPS -$0.86Beat/MissMissed by -$0.51One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersOnKure Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsOnKure Therapeutics' Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile OnKure Therapeutics Q4 2024 Earnings FAQ Did OnKure Therapeutics beat earnings estimates for Q4 2024? OnKure Therapeutics (NASDAQ:OKUR) reported earnings of -$1.37 per share for Q4 2024, missing the consensus estimate of -$0.86. The report was announced on Monday, March 10, 2025. When is OnKure Therapeutics' next earnings date? OnKure Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for OnKure Therapeutics on the company's earnings history page. OnKure Therapeutics Earnings HeadlinesOnkure Therapeutics Inc (OKUR)September 25, 2026 | investing.comOnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare ConferenceAugust 31, 2026 | globenewswire.comHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.October 14 at 1:00 AM | Investors Alley (Ad)OnKure Therapeutics Inc. - Ordinary Shares - Class AAugust 19, 2026 | money.usnews.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), OnKure Therapeutics (OKUR) and Alnylam Pharma (ALNY)August 6, 2026 | theglobeandmail.comOnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business HighlightsAugust 4, 2026 | globenewswire.comSee More OnKure Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email. Email Address About OnKure TherapeuticsOnKure Therapeutics (NASDAQ:OKUR) is a clinical-stage biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research is centered on small-molecule therapies intended to target biological pathways that contribute to tumor growth and immune suppression. OnKure’s lead investigational product is OKN4395, an orally administered EP2 receptor antagonist designed to help restore anti-tumor immune activity within the tumor microenvironment. The company has been evaluating OKN4395 in combination with pembrolizumab, an immune checkpoint inhibitor, for patients with advanced solid tumors. As an investigational therapy, OKN4395 has not been approved for commercial use. Based in Boulder, Colorado, OnKure serves the oncology research and clinical-development market through its drug discovery and clinical programs. The company’s activities are primarily focused on advancing targeted cancer treatments through clinical development and potential regulatory approval.View OnKure Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
